OptimizeRx (NASDAQ:OPRX) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

OptimizeRx (NASDAQ:OPRX) announced its quarterly earnings results on Wednesday. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04, reports. OptimizeRx had a return on equity of 9.65% and a net margin of 5.33%. The firm had revenue of $21.61 million for the quarter, compared to the consensus estimate of $21.19 million.

Here are the key takeaways from OptimizeRx’s conference call:

• OptimizeRx cut its 2026 revenue outlook to $87 million–$93 million, citing customer spending delays and limited visibility into fourth-quarter “buy-ups.” Contracted revenue was about 20% below the comparable prior-year level, increasing the execution risk of meeting the revised range; adjusted EBITDA guidance was maintained at $21 million–$25 million.
• Profitability remained strong despite lower sales: third-quarter revenue fell 17% year over year to $21.6 million, while adjusted EBITDA rose to $6.3 million and margin expanded to about 29% from 20%. Management attributed the improvement to favorable mix, cost reductions, and margin optimization.
• Management cited improving early indicators for 2027, including contracted revenue running about 20% ahead of the comparable point in the prior-year RFP cycle, expanding opportunities in key accounts, and renewed spending from a previously significant customer. Executives said it is too early to provide 2027 guidance, and the returning customer’s spending remains below historical levels.
• Net revenue retention declined to 83%, which management attributed mainly to spending pullbacks at a small number of large accounts rather than broad-based churn. The company is expanding programmatic distribution through DeepIntent, The Trade Desk, and PulsePoint, but said these initiatives are still in the early stages of commercialization.

OptimizeRx Stock Performance

OPRX stock opened at $8.87 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.58 and a quick ratio of 5.58. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $16.37. The company has a market cap of $167.11 million, a P/E ratio of 35.48 and a beta of 1.20. The stock’s fifty day moving average price is $8.44 and its 200-day moving average price is $7.22.

Analyst Upgrades and Downgrades

OPRX has been the subject of several research analyst reports. Citizens Jmp lifted their price objective on OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Friday, August 14th. Weiss Ratings raised shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th. Wall Street Zen downgraded shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a report on Monday, July 20th. UBS Group set a $11.00 price target on shares of OptimizeRx in a research note on Friday, August 14th. Finally, Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a report on Tuesday, October 27th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OptimizeRx has an average rating of “Moderate Buy” and a consensus price target of $11.21.

OptimizeRx Company Profile

OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company’s services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.